Hikma Pharmaceuticals is no stranger to buyout rumors. The Jordan-based drugmaker pops up often in deal talk, partly because of its sales and infrastructure in emerging markets. Now, there's another reason or two--its recent win on the gout drug Mitigare and its impending entry onto London's Financial Times Stock Exchange. New rumors, too.
Pfizer, a deal-minded drugmaker sitting on billions in cash, is more interested in acquiring near-market assets than investing in long-term projects, counting on a blockbuster oncology collaboration to keep its early-stage pipeline afloat.
With its $49.9 billion purchase of Covidien under its belt, Medtronic is laying out goals for life as a combined company. The device giant is planning to transform healthcare delivery by broadening its product offerings and working more closely with hospitals, two strategies that could yield immediate and long-term growth.
MerLion Pharmaceuticals said it is in sustained talks with potenial investors to take its successful Phase II trials of a urinary tract infection application for its finaloxacin antibiotic into Phase III as it moves into a competitive landscape for the fluoroquinolone class of antibiotics with approval for an ear infection treament by the U.S. FDA.
Pfizer, which spent much of last year trying to acquire U.K. giant AstraZeneca, is now sitting on about $33 billion in cash, and the company's deal pedigree has analysts dreaming of major M&A down the line.
Weeks after Medtronic and Covidien won shareholder approval for their $43 billion merger, the companies expect to finalize the deal today after the Irish High Court signed off on the pending acquisition.
On an acquisition trail, U.S.-based Actavis has snapped up Auden Mckenzie, a U.K. generics maker, for £306 million in cash plus royalties.
Two burning questions about Pfizer since the company backed off its ill-fated offer for AstraZeneca last May: Will the U.S.-based drug giant make another swoop at AstraZeneca? If not, who will Pfizer try to buy?
After seemingly taking forever, Sun Pharmaceuticals' $4 billion takeover of the embattled Ranbaxy Laboratories could win final approval as soon as Feb. 2 and close by midmonth. Seller Daiichi Sankyo will be glad to see it go. Sun remains cautious on the inside, more relaxed on the outside.
Everyone makes mistakes--Valeant CEO J. Michael Pearson included. And he's perfectly willing to admit it.